Flash | 15 Jul 2026 10:35:05 ET │ 9 pages US Biotechnology and Pharmaceuticals J&J 2Q26 EPS call read-through: Tremfya and Icotyde deepen I&I momentum CITI'S TAKE J&J (covered by Joanne Wuensch) kicked off Biopharma's EPS season, reporting 2Q top line of $25.3B (+$275M vs. BBG cons) and $2.90/sh (+$0.03/sh) on the bottom. Once again, the Innovative Medicines franchise led the print ($16.4B; +$263M; +6.8% y/y operationally), with Tremfya ($2B; +$215M; +71% y/y) growth momentum intact and Protagonist-partnere ...